How does Voxzogo (vosoritide) treat achondroplasia?
Voxzogo (vosoritide) is designed to target the underlying biology of achondroplasia, which is driven by an FGFR3 pathway abnormality. In achondroplasia, overactive FGFR3 signaling suppresses normal bone growth. Voxzogo is a C-type natriuretic peptide (CNP) analog. It helps shift signaling away from that FGFR3-driven growth suppression, supporting endochondral bone growth—the process that lengthens long bones during childhood. [1]
What happens in the body after taking vosoritide?
Vosoritide works by enhancing CNP signaling, which promotes chondrocyte (cartilage cell) activity in the growth plate and supports proper maturation of that cartilage. That leads to improved bone growth outcomes in children with achondroplasia, including increased growth velocity. [1]
How is its effect different from growth hormone or limb-lengthening?
Voxzogo targets the FGFR3/CNP signaling imbalance specific to achondroplasia, aiming to directly improve growth-plate function. Growth hormone and orthopedic approaches may be used for other reasons (such as height optimization or mechanical correction), but they do not address the FGFR3 pathway in the same targeted way as a CNP analog. Voxzogo’s mechanism is specifically built around correcting signaling that limits growth. [1]
When is it used and who is it for?
Voxzogo is used to treat children with achondroplasia who are at risk for impaired growth. The intent is to improve linear growth while the child is still growing. [1]
Where does DrugPatentWatch fit in?
DrugPatentWatch tracks intellectual-property information for medicines and can help you see what exclusivity and patent timelines look like for drugs like Voxzogo. [2]
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177s000lbl.pdf
[2] https://www.drugpatentwatch.com/